Document is current
Any future updates will be listed below
-
Authors
Yapp, Clarence https://orcid.org/0000-0003-1144-5710
Nirmal, Ajit J. https://orcid.org/0000-0003-4139-0618
Zhou, Felix https://orcid.org/0000-0003-4463-1165
Wong, Alex Y. H. https://orcid.org/0000-0001-9315-4145
Tefft, Juliann B. https://orcid.org/0000-0002-8826-665X
Lu, Yi Daniel https://orcid.org/0009-0003-1740-161X
Shang, Zhiguo https://orcid.org/0000-0002-7600-7554
Maliga, Zoltan https://orcid.org/0000-0003-4209-7253
Llopis, Paula Montero https://orcid.org/0000-0002-5983-2296
Murphy, George F. https://orcid.org/0000-0001-9362-5146
Lian, Christine G.
Danuser, Gaudenz https://orcid.org/0000-0001-8583-2014
Santagata, Sandro https://orcid.org/0000-0002-7528-9668
Sorger, Peter K. https://orcid.org/0000-0002-3364-1838
- License Information
-
More Information
Article History
Received: 29 July 2024
Accepted: 17 August 2025
First Online: 29 September 2025
Competing interests
: P.K.S. is a cofounder and member of the BOD of Glencoe Software, member of the BOD for Applied Biomath and member of the SAB for RareCyte, NanoString, Reverb Therapeutics and Montai Health; he holds equity in Glencoe, Applied Biomath and RareCyte. P.K.S. consults for Merck, and the Sorger lab has received research funding from Novartis and Merck in the past 5 years. The other authors declare no competing interests.
